Aldeyra The (ALDX)
ALDX Stock Price Chart
Explore Aldeyra The interactive price chart. Choose custom timeframes to analyze ALDX price movements and trends.
ALDX Company Profile
Discover essential business fundamentals and corporate details for Aldeyra The (ALDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 May 2014
Employees
8.00
Website
https://www.aldeyra.comCEO
Todd C. Brady
Description
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Financial Timeline
Browse a chronological timeline of Aldeyra The corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.11, while revenue estimate is $31.33m.
Earnings released on 7 May 2026
EPS came in at -$0.06 surpassing the estimated -$0.13 by +53.85%.
Earnings released on 27 Feb 2026
EPS came in at -$0.11 surpassing the estimated -$0.14 by +21.43%.
Earnings released on 5 Nov 2025
EPS came in at -$0.13 surpassing the estimated -$0.17 by +23.53%.
Earnings released on 7 Aug 2025
EPS came in at -$0.16 surpassing the estimated -$0.21 by +23.81%.
Earnings released on 14 May 2025
EPS came in at -$0.17 surpassing the estimated -$0.25 by +32.00%.
Earnings released on 28 Feb 2025
EPS came in at -$0.27 falling short of the estimated -$0.25 by -8.00%, while revenue for the quarter reached $244.53k .
Earnings released on 7 Nov 2024
EPS came in at -$0.25 matching the estimated -$0.25.
Earnings released on 1 Aug 2024
EPS came in at -$0.28 falling short of the estimated -$0.14 by -100.00%.
Earnings released on 2 May 2024
EPS came in at -$0.14 falling short of the estimated -$0.08 by -75.00%.
Earnings released on 7 Mar 2024
EPS came in at -$0.08 surpassing the estimated -$0.21 by +61.90%, while revenue for the quarter reached $392.62k , missing expectations by -86.91%.
Earnings released on 3 Nov 2023
EPS came in at -$0.14 surpassing the estimated -$0.24 by +41.67%.
Earnings released on 3 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.31 by +51.61%.
Earnings released on 4 May 2023
EPS came in at -$0.27 surpassing the estimated -$0.30 by +10.00%.
Earnings released on 9 Mar 2023
EPS came in at -$0.22 surpassing the estimated -$0.34 by +35.29%.
Earnings released on 10 Nov 2022
EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%.
Earnings released on 5 Aug 2022
EPS came in at -$0.30 surpassing the estimated -$0.32 by +6.25%.
Earnings released on 5 May 2022
EPS came in at -$0.29 surpassing the estimated -$0.31 by +6.45%.
Earnings released on 17 Mar 2022
EPS came in at -$0.27 surpassing the estimated -$0.31 by +12.90%.
Earnings released on 28 Oct 2021
EPS came in at -$0.27 surpassing the estimated -$0.29 by +6.90%.
Earnings released on 5 Aug 2021
EPS came in at -$0.28 falling short of the estimated -$0.27 by -3.70%.
ALDX Stock Performance
Access detailed ALDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
